Literature DB >> 23180346

Multidisciplinary management of locally advanced-borderline resectable adenocarcinoma of the head of the pancreas.

F Calvo1, C Guillen Ponce, M Muñoz Beltran, A Sanjuanbenito Dehesa.   

Abstract

Borderline resectable pancreatic head carcinoma is a challenging disease that requires multidisciplinary approach to obtain maximal benefits from current therapeutical possibilities. We review current knowledge and therapeutic options for the patients from the surgical, medical oncology and radiotherapy views and emphasize the need for a coordinated multidisciplinary approach to obtain optimal results.

Entities:  

Mesh：

Year:  2012        PMID： 23180346     DOI： 10.1007/s12094-012-0962-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  89 in total

1.  Preoperative assessment of pancreatic malignancy using endoscopic ultrasound.

Authors:  I F Yusoff; R M Mendelson; S E J Edmunds; D Ramsay; G L Cullingford; D R Fletcher; A M J Zimmerman
Journal:  Abdom Imaging       Date:  2003 Jul-Aug

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

Review 3.  Laparoscopy in the staging of pancreatic cancer.

Authors:  P W Pisters; J E Lee; J N Vauthey; C Charnsangavej; D B Evans
Journal:  Br J Surg       Date:  2001-03       Impact factor: 6.939

4.  Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.

Authors:  Rebekah R White; H Bill Xie; Marcia R Gottfried; Brian G Czito; Herbert I Hurwitz; Michael A Morse; Gerald C Blobe; Erik K Paulson; John Baillie; M Stanley Branch; Paul S Jowell; Bryan M Clary; Theodore N Pappas; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2005-03-03       Impact factor: 5.344

5.  Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.

Authors:  Jerome Landry; Paul J Catalano; Charles Staley; Wayne Harris; John Hoffman; Mark Talamonti; Natalie Xu; Harry Cooper; Al B Benson
Journal:  J Surg Oncol       Date:  2010-06-01       Impact factor: 3.454

Review 6.  Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.

Authors:  Sheetal M Kircher; Seth B Krantz; Halla S Nimeiri; Mary F Mulcahy; Hidayatullah G Munshi; Al B Benson
Journal:  Expert Rev Anticancer Ther       Date:  2011-10       Impact factor: 4.512

7.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

8.  Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.

Authors:  H Golcher; T Brunner; G Grabenbauer; S Merkel; T Papadopoulos; W Hohenberger; T Meyer
Journal:  Eur J Surg Oncol       Date:  2008-01-10       Impact factor: 4.424

9.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Authors:  Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

10.  Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.

Authors:  Kimberly M Brown; Veeriah Siripurapu; Marson Davidson; Steven J Cohen; Andre Konski; James C Watson; Tiaynu Li; Vince Ciocca; Harry Cooper; John P Hoffman
Journal:  Am J Surg       Date:  2008-03       Impact factor: 2.565
View more
  4 in total

Review 1.  Management of borderline and locally advanced pancreatic cancer: where do we stand?

Authors:  Jin He; Andrew J Page; Matthew Weiss; Christopher L Wolfgang; Joseph M Herman; Timothy M Pawlik
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

2.  Role of radiotherapy in the chemotherapy-containing multidisciplinary management of patients with resected pancreatic adenocarcinoma.

Authors:  Claudio V Sole; Felipe A Calvo; Freddy Atahualpa; Alejandro Berlin; Rafael Herranz; Luis Gonzalez-Bayon; Jose Luis García-Sabrido
Journal:  Strahlenther Onkol       Date:  2014-10-08       Impact factor: 3.621

3.  Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.

Authors:  Marine Gilabert; Brice Chanez; Young Soo Rho; Marc Giovanini; Olivier Turrini; Gerald Batist; Petr Kavan; Jean Luc Raoul
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

4.  Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS UR-01).

Authors:  Yasutoshi Kimura; Toru Nakamura; Tsuyoshi Hayashi; Masaki Kuwatani; Masayo Motoya; Makoto Yoshida; Masafumi Imamura; Minoru Nagayama; Hiroshi Yamaguchi; Keisuke Yamakita; Takuma Goto; Yusuke Sakuhara; Kuniyuki Takahashi; Hiroyuki Maguchi; Satoshi Hirano; Ichiro Takemasa
Journal:  Ann Gastroenterol Surg       Date:  2019-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.